lapatinib has been researched along with Adenocarcinoma, Basal Cell in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.11) | 29.6817 |
| 2010's | 30 (81.08) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F; Ma, L; Niu, Y; Yan, C; Zhao, W | 1 |
| Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F | 1 |
| Hou, Y; Liu, Y; Xue, L; Zhao, L | 1 |
| Church, AJ; DuBois, SG; Janeway, KA; McCleary, NJ; Prensner, JR; Putra, J; Vargas, SO | 1 |
| Agarwal, R; Grieb, BC | 1 |
| An, J; Bae, JM; Banks, KC; Bass, AJ; Choi, MG; Kang, WK; Kim, K; Kim, NKD; Kim, S; Kim, ST; Kim, SY; Lanman, RB; Lee, H; Lee, J; Lee, JH; Lim, HY; Park, JO; Park, SH; Park, W; Park, YS; Pectasides, E; Sohn, TS; Talasaz, A | 1 |
| Amatu, A; Arcella, P; Balsamo, A; Bardelli, A; Bartolini, A; Bertotti, A; Bonazzina, E; Cappello, G; Cassingena, A; Corti, G; Crisafulli, G; Di Nicolantonio, F; Fairclough, S; Ghezzi, S; Lanman, RB; Lazzari, L; Leone, F; Lodi, F; Lonardi, S; Lorenzato, A; Marsoni, S; Martino, C; Montone, M; Mussolin, B; Nagy, RJ; Regge, D; Rospo, G; Russo, M; Sartore-Bianchi, A; Siena, S; Siravegna, G; Truini, M; Trusolino, L; Valtorta, E; Vanzati, A; Vanzulli, A; Zagonel, V | 1 |
| Adams, O; Bütler, V; Dislich, B; Janser, FA; Kröll, D; Langer, R; Schläfli, AM; Seiler, CA; Tschan, MP | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS | 1 |
| Bachelot, T; Bernard-Marty, C; Bonneterre, J; Conforti, R; Le Rhun, E; Taillibert, S | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
| Cheow, H; De Silva, N; Fitzgerald, R; Ford, H; Godfrey, E; Hochhauser, D; Jobanputra, M; Lao-Sirieix, P; O'Donovan, M; Paterson, A; Qain, W; Schulz, L; Secrier, M | 1 |
| Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Ellis, CE; Estrada, MC; Gagnon, RC; Grob, TJ; Hecht, JR; Jeziorski, K; Liang, Z; Ma, Y; Park, JO; Press, MF; Qin, SK; Robinson, DM; Sauter, G; Scherer, SJ; Slamon, DJ; Villalobos, I; Wu, S; Xu, J | 1 |
| Baltazar, F; Barbosa, AM; Cardoso-Carneiro, D; Cury, FP; de Paula, FE; Evangelista, AF; Granja, S; Longatto-Filho, A; Marques, F; Martinho, O; Miranda-Gonçalves, V; Moreira, MA; Reis, RM; Scapulatempo-Neto, C; Silva-Oliveira, R; Zanon, M | 1 |
| Chin, JL; Dancey, JE; Gregg, R; Hedley, D; Hotte, SJ; Hudes, GR; Moore, MJ; Pham, NA; Sridhar, SS; Trachtenberg, J; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Jørgensen, JT | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Cunningham, D; Okines, AF | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Armstrong, AJ; Crane, JM; George, DJ; Godley, PA; Grigson, G; Kim, WY; Moore, DT; Morris, K; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, CP; Whang, YE | 1 |
| Blanke, CD; Danenberg, KD; Fenoglio-Preiser, CM; Goldman, B; Iqbal, S; Lenz, HJ; Shibata, SI; Zhang, W | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Dasanu, CA; Kaur, A | 1 |
| Kołodziejczyk, P; Kulig, J; Kulig, P; Legutko, J | 1 |
| Abulafia, O; Fischer, EG; Godwin, AK; Gray, H; Hanjani, P; Lankes, HA; Leslie, KK; Rose, PG; Schilder, RJ; Sill, MW; Tewari, K; Walker, JL | 1 |
| Bastida, CC; Falchook, GS; Janku, F; Kurzrock, R; Stewart, DJ; Tsao, AS | 1 |
| Laurie, SA; Licitra, L | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
6 review(s) available for lapatinib and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Selected updates in molecular and genomic pathology of esophageal cancer.
Topics: Adenocarcinoma; Alphapapillomavirus; Antineoplastic Agents, Immunological; B7-H1 Antigen; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lapatinib; Papillomavirus Infections; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab | 2020 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Neoplasm; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lapatinib; Oxaliplatin; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2021 |
[Systemic treatment of brain metastases from breast cancer].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Medicine; Molecular Targeted Therapy; Patient Care Team; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Esophageal Neoplasms; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Targeted therapy for gastric cancer--current status.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drugs, Investigational; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
15 trial(s) available for lapatinib and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell-Free System; Female; Humans; Lapatinib; Male; Middle Aged; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Young Adult | 2018 |
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Clinical Decision-Making; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Italy; Lapatinib; Liquid Biopsy; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Predictive Value of Tests; Progression-Free Survival; Protein Kinase Inhibitors; ras Proteins; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured | 2018 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Lapatinib; Male; MAP Kinase Signaling System; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2015 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome; Young Adult | 2017 |
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2010 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Castration; ErbB Receptors; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate | 2013 |
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2011 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Drug Administration Schedule; Endometrial Neoplasms; Female; Genes, erbB-1; Genetic Markers; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
16 other study(ies) available for lapatinib and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Biomarkers, Tumor; DNA-Binding Proteins; Epothilones; Gene Expression Regulation, Neoplastic; Humans; Interleukin-18; Lapatinib; Pancreatic Neoplasms; Pore Forming Cytotoxic Proteins; Prognosis; Pyroptosis | 2022 |
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Agents; Humans; Lapatinib; Male; Neoplasms, Unknown Primary; Precision Medicine | 2021 |
Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; HEK293 Cells; Humans; Lapatinib; Receptor, ErbB-2 | 2018 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms | 2014 |
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Topics: Acrylamides; Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Biomarkers, Tumor; Diagnostic Tests, Routine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glucose; Humans; Lapatinib; Quinazolines; Theranostic Nanomedicine; Therapeutic Uses; Uterine Cervical Neoplasms | 2017 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
Trastuzumab in gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Forecasting; Genes, erbB-2; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Exons; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2013 |